share_log
Benzinga ·  Apr 29 10:49
Annovis Bio Shares Are Trading Lower After the Company Announced Data From Its Phase II/III Alzheimer Study of Buntanetap in Mild to Moderate Alzheimer's. Efficacy in the CGIC Endpoint Was Not Reached Due to the Limited Number of Patients and Short Trial Duration
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment